The Global Coated Endotracheal Tube Market size is expected to reach $238.2 million by 2030, rising at a market growth of 6.1% CAGR during the forecast period. In the year 2022, the market attained a volume of 9,493.1 thousand units experiencing a growth of 8.9% (2019-2022).
Respiratory conditions, including those requiring intubation, are prevalent in the Asia Pacific region. There is a growing awareness among healthcare professionals in the APAC region regarding the latest advancements in medical technologies. Consequently, the Asia Pacific region would acquire nearly 30% of the total market share by 2030. The growth of medical tourism increases the demand for advanced medical facilities and technologies in the region. These tubes, known for their benefits in respiratory care, contribute to the attractiveness of healthcare facilities in the Asia Pacific region. Some of the factors impacting the market are the growing prevalence of respiratory diseases, the increasing number of senior citizens and the high initial cost of these tubes.
The rising incidence of respiratory diseases globally drives the demand for advanced respiratory care solutions. These tubes, with their features aimed at minimizing complications, are increasingly used to manage respiratory diseases, contributing to market growth. Ventilator-associated pneumonia (VAP) is a common complication in ventilated patients with respiratory diseases. These tubes with anti-microbial properties play a crucial role in preventing VAP. By reducing the risk of respiratory infections, these tubes contribute to better outcomes for patients with respiratory diseases. The market is expanding significantly due to the growing prevalence of respiratory diseases. Additionally, as per the WHO, one in six people will be 60 or older by 2030. The number of people 60 and older in the world will increase from 1 billion in 2020 to 1.4 billion in 2050. By 2050, there will be 2.1 billion people in the world who are 60 or older. It is anticipated that there will be 426 million persons 80 or older by 2050. Elderly patients often have unique healthcare needs, including a focus on comfort and well-being. These tubes, with features such as smoother surfaces and reduced friction, enhance patient comfort during intubation and ventilation. As a result of the increasing number of senior citizens, the market is anticipated to increase significantly.
Moreover, the surge in COVID-19 cases led to an increased demand for mechanical ventilation and, consequently, endotracheal intubation in severe cases. The risk of healthcare-associated infections, including VAP, became a critical concern during the pandemic. The pandemic prompted a shift in healthcare priorities, with an increased focus on critical care, respiratory support, and infection control measures. Thus, the COVID-19 pandemic had a positive effect on the market.
However, these tubes often cost more upfront than traditional uncoated tubes. The cost factor can be a barrier to adoption, particularly in healthcare systems where budget constraints are a significant concern. Reimbursement policies may not always align with the higher cost of advanced medical technologies. Healthcare providers may face challenges in securing adequate reimbursement for these tubes. This discrepancy between cost and reimbursement can discourage adoption, particularly if it affects the financial viability of healthcare institutions. Thus, high initial cost of these tubes can slow down the growth of the market.
Intubation Outlook
Based on intubation, the market is classified into orotracheal and nasotracheal. The nasotracheal segment acquired a substantial revenue share in the market in 2022. Nasotracheal intubation involves the passage of the tube through the smaller nasal passages, and coated tubes can contribute to smoother insertion, minimizing trauma. The reduced friction can be particularly beneficial in nasotracheal intubation procedures, potentially leading to increased adoption. These tubes, with their anti-microbial properties, contribute to infection prevention measures during nasotracheal intubation.
End User Outlook
By end user, the market is categorized into hospitals, clinics, and ambulatory surgical centres. The clinics segment covered a considerable revenue share in the market in 2022. Clinics increasingly incorporate innovative healthcare technologies into their practices, including advanced endotracheal tubes with smart features. Integrating smart technologies, such as sensors and monitoring capabilities, enhances patient monitoring and facilitates real-time data collection in clinic settings. This drive for innovation contributes to adopting these tubes with advanced functionalities.
Application Outlook
On the basis of application, the market is divided into anesthesia, emergency medicine, and others. The emergency medicine segment recorded a remarkable revenue share in the market in 2022. Emergency medicine involves many clinical scenarios, from trauma cases to respiratory distress. Emergency medicine often deals with trauma cases and critical interventions requiring rapid intubation. These tubes, focusing on reducing complications and providing a smooth intubation process, are valuable in managing trauma cases and critical emergencies, improving the efficiency of airway management.
Regional Outlook
Region-wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the North America region led the market by generating the highest revenue share. Patient safety and care quality are paramount concerns within North America’s healthcare system. North America boasts advanced healthcare infrastructure and a robust medical technology landscape. The region’s well-developed healthcare facilities are more inclined to adopt innovative technologies, including these tubes. The region’s higher incidence of respiratory challenges drives the demand for technologies that minimize complications.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Sonoma Pharmaceuticals Inc., Becton, Dickinson, and Company, Bactiguard Holding AB (publ), Sharklet Technologies, Inc., Medline Industries, LP, N8 Medical, LLC, Armstrong Medical Ltd (Eakin Healthcare Ltd), Teleflex, Inc. and Venner Medical (Deutschland) GmbH
Scope of the Study
Market Segments covered in the Report:
By Intubation (Volume, Thousand Units, USD Million, 2019-2030)

  • Orotracheal
  • Nasotracheal


By End User (Volume, Thousand Units, USD Million, 2019-2030)

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers


By Application (Volume, Thousand Units, USD Million, 2019-2030)

  • Anesthesia
  • Emergency Medicine
  • Others


By Geography (Volume, Thousand Units, USD Million, 2019-2030)

  • North America


o US
o Canada
o Mexico
o Rest of North America

  • Europe


o Germany
o UK
o France
o Russia
o Spain
o Italy
o Rest of Europe

  • Asia Pacific


o China
o Japan
o India
o South Korea
o Singapore
o Malaysia
o Rest of Asia Pacific

  • LAMEA


o Brazil
o Argentina
o UAE
o Saudi Arabia
o South Africa
o Nigeria
o Rest of LAMEA
Companies Profiled

  • Sonoma Pharmaceuticals Inc.
  • Becton, Dickinson, and Company
  • Bactiguard Holding AB (publ)
  • Sharklet Technologies, Inc.
  • Medline Industries, LP
  • N8 Medical, LLC
  • Armstrong Medical Ltd (Eakin Healthcare Ltd)
  • Teleflex, Inc.
  • Venner Medical (Deutschland) GmbH


Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free